正元胶囊治疗结直肠癌的药理机制:网络药理学与实验验证
本研究结合网络药理学分析与CT26皮下移植瘤模型实验,探讨正元胶囊(ZYJN)的抗结直肠癌作用及机制。结果表明ZYJN单用或联合5-FU均抑制肿瘤生长,联合5-FU可提高白蛋白、降低AST和VEGF,并调节肿瘤免疫微环境。机制涉及抑制PI3K/Akt通路、减少血管生成和调节免疫细胞浸润。
要点
- 正元胶囊单用或联合5-FU均可抑制CT26结直肠癌生长。
- 联合5-FU可改善血清白蛋白和AST水平,降低VEGF。
- 机制涉及抑制PI3K/Akt通路、减少血管生成和调节免疫微环境。
核心结论
- 正元胶囊通过促进肿瘤纤维化、抑制血管生成与迁移侵袭、调节肿瘤免疫微环境抑制CT26结直肠癌生长。
- 正元胶囊联合化疗可增强疗效并降低化疗药物毒性。
研究设计与样本
- 采用高效液相色谱法对正元胶囊进行指纹图谱分析。
- 利用生物信息学分析预测正元胶囊的潜在靶点,并用Western Blot验证。
- 建立CT26皮下移植瘤模型评估正元胶囊的抗肿瘤作用。
- 采用流式细胞术研究正元胶囊对肿瘤免疫微环境的影响。
- 采用透明成像技术研究正元胶囊对纤维化和血管生成的影响。
主要发现
- 正元胶囊单用或联合5-FU均可抑制结直肠癌生长。
- 正元胶囊(0.75 g/kg)联合5-FU可显著降低血清VEGF水平并抑制CT26肿瘤血管生成。
- 正元胶囊(1.50 g/kg)联合5-FU可促进CT26肿瘤纤维化进程。
- 正元胶囊联合5-FU可显著增加CT26模型晚期肿瘤浸润T细胞和CD4+ T细胞比例。
- 正元胶囊(1.50 g/kg)在CT26模型早期增加NK细胞和CD8+ T细胞比例。
关键数值与推荐
- 正元胶囊联合5-FU可显著提高血清白蛋白(ALB)水平并降低血清天冬氨酸氨基转移酶(AST)水平。
- 正元胶囊0.75 g/kg联合5-FU可显著降低血清VEGF水平并抑制CT26肿瘤血管生成。
- 正元胶囊1.50 g/kg联合5-FU可促进CT26肿瘤纤维化。
- 正元胶囊0.75 g/kg降低PI3K-p110α、CDK1、CCNB1和MMP-9表达,抑制Akt(Thr308)磷酸化。
临床怎么用
- 正元胶囊可作为结直肠癌的辅助治疗药物,与5-FU联合使用可能增强疗效并减轻化疗毒性。
- 临床可关注正元胶囊对血清白蛋白、AST和VEGF水平的影响,以及免疫细胞浸润的变化。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
ETHNOPHARMACOLOGICAL RELEVANCE: Zhengyuan jiaonang (ZYJN) is a traditional Chinese patent medicine (CPM) used in China for adjuvant cancer therapy, which has been proved to have anti-fatigue effects. AIM OF STUDY: The study aims to investigate the antitumor effects of ZYJN and its underlying mechanisms using subcutaneous transplant CT26 model. MATERIALS AND METHODS: Fingerprint analysis of ZYJN was performed using high performance liquid chromatography. The potential targets of ZYJN were predicted using bioinformatic analysis, which were further validated by Western Blot assay. Subcutaneous transplant CT26 model was used to evaluate the antitumor effects of ZYJN. The effects of ZYJN on the tumor immune microenvironment were investigated by flow cytometry. Transparent imaging was used to investigate the effects of ZYJN on fibrosis and angiogenesis. RESULTS: ZYJN could inhibit colorectal cancer growth when administered alone or in combination with 5-FU. The combination of ZYJN and 5-FU could significantly increase the serum level of albumin (ALB) and decrease the serum level of aspartate aminotransferase (AST). In addition, the combination of ZYJN at 0.75 g/kg and 5-FU significantly decreased the serum level of vascular endothelial growth factors (VEGF) and inhibited the angiogenesis of CT26 cancer. The combination of ZYJN at 1.50 g/kg and 5-FU could promote the fibrosis process of CT26 cancer. Additionally, combination of ZYJN and 5-FU could significantly increase the percentage of tumor-infiltrating T cells and CD4+ T cells in the late stage of CT26 model, while ZYJN at 1.50 g/kg increased the percentage of NK cells as well as CD8+ T cells in the early stage of CT26 model. Western Blot analysis revealed that administration of ZYJN at 0.75 g/kg reduced the expression of PI3K-p110α, CDK1, CCNB1 and MMP-9, and inhibited the phosphorylation of Akt (Thr308). CONCLUSIONS: ZYJN could inhibit the tumor growth of CT26 colorectal cancer by promoting tumor fibrosis, suppressing angiogenesis, migration, and invasion and modulating the tumor immune microenvironment. ZYJN enhanced the efficacy and reduced the toxicity of chemotherapy drugs in combination therapy. Our findings provide evidence for the clinical application of ZYJN in cancer treatment.
引用
- Deng H, Liu S, Li D, et al. Investigating the pharmacological mechanism of Zhengyuan jiaonang for treating colorectal cancer via network pharmacology analysis and experimental verification. J Ethnopharmacol. 2023. PMID: 38110132. doi:10.1016/j.jep.2023.117607
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。